切换至 "中华医学电子期刊资源库"
高级检索
中华妇幼临床医学杂志(电子版)

中华妇幼临床医学杂志(电子版) ›› 2020, Vol. 16 ›› Issue (01) : 100 -106. doi: 10.3877/cma.j.issn.1673-5250.2020.01.013

所属专题： 文献；

论著

淋巴细胞与单核细胞比值对早期宫颈癌患者盆腔淋巴结转移的预测价值
唐英1, 唐方祥1, 胡辉权1,†(), 徐凡1, 宾冬梅2   
  1. 1. 川北医学院附属南充市中心医院妇科，四川　637000
    2. 南充市妇幼保健院，四川　637000
  • 收稿日期:2019-10-18 修回日期:2020-01-07 出版日期:2020-02-01
  • 通信作者: 胡辉权

Predictive value of preoperative lymphocyte-to-monocyte ratio on pelvic lymph node metastasis of early cervical cancer patients

Ying Tang1, Fangxiang Tang1, Huiquan Hu1,†(), Fan Xu1, Dongmei Bin2   

  1. 1. Department of Gynecology, Affiliated Nanchong Central Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China
    2. Nanchong Maternal and Child Care Service Centre, Nanchong 637000, Sichuan Province, China
  • Received:2019-10-18 Revised:2020-01-07 Published:2020-02-01
  • Corresponding author: Huiquan Hu
  • About author:
    Corresponding author: Hu Huiquan, Email:
  • Supported by:
    Science & Technology Program by Science & Technology Department of Sichuan Province(2015JY0056); Program by Bureau of Science & Technology and Intellectual Property of Nanchong City, Sichuan Province(17YFZJ0005, 18YFZJ0012)
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

唐英, 唐方祥, 胡辉权, 徐凡, 宾冬梅. 淋巴细胞与单核细胞比值对早期宫颈癌患者盆腔淋巴结转移的预测价值[J/OL]. 中华妇幼临床医学杂志(电子版), 2020, 16(01): 100-106.

Ying Tang, Fangxiang Tang, Huiquan Hu, Fan Xu, Dongmei Bin. Predictive value of preoperative lymphocyte-to-monocyte ratio on pelvic lymph node metastasis of early cervical cancer patients[J/OL]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2020, 16(01): 100-106.

目的

探讨淋巴细胞与单核细胞比值(LMR)对早期宫颈癌患者盆腔淋巴结转移(PLNM)的预测价值。

方法

选择2008年1月至2018年1月，于川北医学院附属南充市中心医院初次接受宫颈癌根治性术的516例早期宫颈癌患者为研究对象。根据是否发生PLNM，将其分为PLNM(＋)组(n＝113)和PLNM(－)组(n＝403)。采用回顾性分析法，分析所有受试者的临床病例资料。采用χ2检验，对2组患者年龄、国际妇产科联盟(FIGO)临床分期，手术切除组织的病理学分级、组织病理学类型、肿瘤直径、血清鳞状细胞癌抗原(SCC-Ag)含量，术中是否发现脉管癌栓、宫旁浸润，宫颈间质浸润深度，以及LMR构成比等进行统计学比较。绘制LMR预测宫颈癌PLNM的受试者工作特征(ROC)曲线，对LMR预测早期宫颈癌患者发生PLNM进行分析，并计算ROC曲线下面积(ROC-AUC)。采用多因素非条件logistic回归分析，判断LMR预测早期宫颈癌患者发生PLNM的准确性。本研究遵循的程序符合2013年修订的《世界医学协会赫尔辛基宣言》要求。2组患者年龄比较，差异无统计学意义(P>0.05)。

结果

①单因素分析结果：PLNM(＋)组与PLNM(－)组患者FIGO临床分期、手术切除组织的病理学分级、组织病理学类型、肿瘤直径、血清SCC-Ag含量、术中是否发现脉管癌栓及宫旁浸润、宫颈间质浸润深度、LMR构成比比较，差异均有统计学意义(χ2＝13.057、18.998、9.584、85.667、7.225、88.538、69.807、32.644、126.453，P<0.05)。②多因素非条件logistic回归分析结果：早期宫颈癌患者FIGO临床分期为ⅡA期(OR＝2.805，95%CI：1.224～4.160，P＝0.009)，手术切除组织的病理学分级为G1(OR＝2.256，95%CI：1.245～6.323，P＝0.013)，脉管癌栓(OR＝5.818，95%CI：3.139～10.782，P<0.001)，宫旁浸润(OR＝4.482，95%CI：1.730～11.615，P<0.002)，肿瘤直径≥4 cm(OR＝3.955，95%CI：2.119～7.383，P<0.001)，以及血清SCC-Ag含量≥1.6 ng/mL(OR＝1.909，95%CI：1.057～3.446，P＝0.032)，均为早期宫颈癌患者发生PLNM的危险因素，而LMR>2.2(OR＝0.155，95%CI：0.081～0.296，P<0.001)，则为早期宫颈癌患者发生PLNM的保护因素。③ROC曲线分析结果：LMR预测早期宫颈癌患者PLNM的ROC-AUC为0.790(95%CI：0.753～0.825，P<0.001)。根据约登指数(Youden index)最大原则，LMR预测早期宫颈癌患者发生PLNM的最佳临界值为2.2，此时其预测早期宫颈癌患者发生PLNM的敏感度为66.4%，特异度为85.9%。

结论

术前外周血LMR>2.2，可作为预测早期宫颈癌发生PLNM的保护因素。

关键词: 宫颈肿瘤, 肿瘤，鳞状细胞, 淋巴细胞与单核细胞比值, 淋巴转移, 淋巴细胞，肿瘤浸润, ROC曲线, 妇女
Objective

To explore the value of lymphocyte-to-monocyte ratio (LMR) on pelvic lymph node metastasis (PLNM) of early cervical cancer patients.

Methods

The clinical and pathological data of 516 patients with early cervical cancer whose initial treatment were radical hysterectomy in the Affiliated Nanchong Central Hospital of North Sichuan Medical College from January 2008 to January 2018 were selected into this study. According to being accompanied with PLNM or not, they were divided into PLNM (+ ) group (n=113) and PLNM(-)group (n=403). Retrospective analysis was used to analyze clinical data of all subjects. Chi-square was used to statistically compare the proportions of the age, International Federation of Gynecology and Obstetrics (FIGO) clinical stages, histopathological grades, histopathological types, vessel carcinoma embolus, parametrial invasion, cervical interstitial invasion depth, tumor diameters, levels of serum squamous cell carcinoma antigen(SCC-Ag), LMR between two groups. The receiver operating characteristic (ROC) curve of LMR predicting PLNM in early cervical cancer patients was drawn and analyzed, and the area under ROC curve (ROC-AUC) was calculated. The accuracy of LMR in the prediction of PLNM in early cervical cancer patients was evaluated by multivariate unconditional logistic regression analysis. This study met the requirements of the World Medical Association Declaration of Helsinki revised in 2013. There was no significant difference between two groups in age (P>0.05).

Results

①The results of univariate analysis showed that there were significant differences in proportions of FIGO clinical stages, histopathological grades, histopathological types, tumor diameters, levels of serum SCC-Ag, vessel carcinoma embolus, parametrial invasion, depth of cervical interstitial invasion and LMR (χ2=13.057, 18.998, 9.584, 85.667, 7.225, 88.538, 69.807, 32.644, 126.453; P<0.05). ②The results of multivariate unconditional logistic regression analysis showed that FIGO clinical stage ⅡA (OR=2.805, 95%CI: 1.224-4.160, P=0.009), histopathological grade G1 (OR=2.256, 95%CI: 1.245-6.323, P=0.013), vessel carcinoma embolus (OR=5.818, 95%CI: 3.139-10.782, P<0.001), parametrial invasion (OR=4.482, 95%CI: 1.730-11.615, P<0.002), tumor diameters≥4 cm (OR=3.955, 95%CI: 2.119-7.383, P<0.001), levels of serum SCC-Ag≥1.6 ng/mL (OR=1.909, 95%CI: 1.057-3.446, P=0.032) were risk factors of PLNM in early cervical cancer patients, while LMR > 2.2 (OR=0.155, 95%CI: 0.081-0.296, P<0.001) was the protective factor of PLNM in early cervical cancer patients. ③The ROC curve of LMR predicting PLNM of early cervical cancer showed that the ROC-AUC was 0.790 (95%CI: 0.753-0.825, P<0.001). According to the maximum principle of the Youden index, the optimal cut-off value of LMR predicting PLNM in patients with early cervical cancer was 2.2, and the sensitivity and specificity were 66.4% and 85.9%, respectively.

Conclusion

Peripheral blood LMR>2.2 is an independent protective factor to predict PLNM of early cervical cancer.

Key words: Uterine cervical neoplasms, Neoplasms, squamous cell, Lymphocyte-to-monocyte ratio, Lymphatic metastasis, Lymphocytes, tumor-infiltrating, ROC curve, Women
表1 本组516例早期宫颈癌患者的一般临床资料
项目 结果 项目 结果
年龄[岁，M(P25～P75)] 49(28～72) 宫旁浸润[例数(%)] ?
BMI[kg/m2，M(P25～P75)] 23.7(16.5～32.0) ? 阳性 45(8.7)
FIGO临床分期[例数(%)] ? ? 阴性 471(91.3)
? ⅠB期 402(77.9) 脉管癌栓[例数(%)] ?
? ⅡA期 114(22.1) ? 阳性 471(91.3)
组织病理学类型[例数(%)] ? ? ? 阴性
? 鳞癌 406(78.7) 宫颈间质浸润深度[例数(%)] ?
? 腺癌 103(20.0) ? >2/3 180(34.9)
? 腺鳞癌 6(1.1) ? ≤2/3 336(65.1)
? 其他类型 1(0.2) 腹膜后淋巴结转移[例数(%)] ?
组织病理学分级[例数(%)] ? ? 阳性 403(78.1)
? G1 56(10.8) ? 阴性 113(21.9)
? G2 390(75.6) 肿瘤直径[cm，M(P25～P75)] 2.5(0.1～11.0)
? G3 70(13.6) 血清SCC-Ag含量[ng/mL，M(P25～P75)] 1.6(0.6～54.5)
单核细胞计数[×109/L，M(P25～P75)] 0.6(0.1～4.8) 淋巴细胞计数[×109/L，M(P25～P75)] 1.8(0.3～7.1)
表2 2组早期宫颈癌患者发生盆腔淋巴结转移影响因素的单因素分析结果[例数(%)]
组别 例数 年龄 FIGO临床分期 手术切除组织病理学分级
<49岁 ≥49岁 ⅠB期 ⅡA期 G1 G2/G3
PLNM(＋)组 113 51(45.1) 62(54.9) 63(55.8) 50(44.2) 25(22.1) 88(77.9)
PLNM(－)组 403 190(47.1) 213(52.9) 296(73.4) 107(26.6) 31(7.7) 372(92.3)
χ2值 ? 0.144 13.057 18.998
P值 ? 0.705 <0.001 <0.001
组别 例数 组织病理学类型 脉管癌栓 宫旁浸润
鳞癌 非鳞癌 阳性 阴性 阳性 阴性
PLNM(＋)组 113 77(68.1) 36(31.9) 81(71.7) 32(28.3) 32(28.3) 81(71.7)
PLNM(－)组 403 329(81.6) 74(18.4) 97(24.0) 306(76.0) 13(3.2) 390(96.8)
χ2值 ? 9.584 88.538 69.807
P值 ? 0.002 <0.001 <0.001
组别 例数 宫颈间质浸润深度 肿瘤直径 血清SCC-Ag含量
≥2/3 <2/3 >4 cm ≤4 cm ≥1.6 ng/mL <1.6 ng/mL
PLNM(＋)组 113 65(57.5) 48(42.5) 58(51.3) 55(48.7) 70(61.9) 43(38.1)
PLNM(－)组 403 115(28.5) 288(71.5) 47(11.7) 356(88.3) 192(47.6) 211(52.4)
χ2值 ? 32.644 85.667 7.225
P值 ? <0.001 <0.001 0.007
组别 例数 LMR
≤2.2 >2.2
PLNM(＋)组 113 75(66.4) 38(33.6)
PLNM(－)组 403 57(14.1) 346(85.9)
χ2值 ? 126.453
P值 ? <0.001
表3 早期宫颈癌患者发生盆腔淋巴结转移影响因素的多因素非条件logistic回归分析变量含义及赋值
自变量/因变量 变量名 赋值
PLNM y y＝0表示早期宫颈癌患者PLNM(－)；y＝1表示早期宫颈癌患者PLNM(＋)
FIGO临床分期 x1 x1＝0表示FIGO临床分期为ⅠB期；x1＝1表示FIGO临床分期为ⅡA期
组织病理学分级 x2 x2＝0表示手术切除组织病理学分级为G2和G3；x2＝1表示手术切除组织病理学分级为G1
组织病理学类型 x3 x3＝0表示除鳞癌外的其他组织病理学类型；x3＝1表示鳞癌
脉管癌栓 x4 x4＝0表示未合并脉管癌栓；x4＝1表示合并脉管癌栓
宫旁浸润 x5 x5＝0表示未合并宫旁浸润；x5＝1表示合并宫旁浸润
宫颈间质浸润深度 x6 x6＝0表示宫颈间质浸润深度<2/3；x6＝1表示宫颈间质浸润深度≥2/3
肿瘤直径 x7 x7＝0表示肿瘤直径≤4 cm；x7＝1表示肿瘤直径>4 cm
血清SCC-Ag含量 x8 x8＝0表示血清SCC-Ag含量<1.6 ng/mL；x8＝1表示血清SCC-Ag含量≥1.6 ng/mL
LMR x9 x9＝0表示LMR≤2.2；x9＝1表示LMR>2.2
表4 早期宫颈癌患者发生盆腔淋巴结转移影响因素的多因素非条件logistic回归分析结果
影响因素 B SE Wald值 P值 OR值 OR值95%CI
常数项 －2.549 0.485 27.664 <0.001 0.078 —
FIGO临床分期 0.814 0.312 6.800 0.009 2.256 1.224～4.160
组织病理学分级 1.032 0.415 6.190 0.013 2.805 1.245～6.323
组织病理学类型 0.365 0.354 1.063 0.303 1.440 0.720～2.882
脉管癌栓 1.761 0.315 31.299 <0.001 5.818 3.139～10.782
宫旁浸润 1.500 0.486 9.537 0.002 4.482 1.730～11.615
宫颈间质浸润深度 －0.056 0.320 0.031 0.861 0.945 0.505～1.770
肿瘤直径 1.375 0.319 18.636 <0.001 3.955 2.119～7.383
血清SCC-Ag含量 0.064 0.301 4.600 0.032 1.909 1.057～3.446
LMR －1.864 0.330 31.887 <0.001 0.155 0.081～0.296
图1 LMR预测早期宫颈癌患者发生PLNM的ROC曲线
[1]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018 [J]. CA Cancer J Clin, 2018, 68(1): 7-30. DOI: 10.3322/caac.21442.
[2]
Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011, 61(2): 69-90. DOI: 10.3322/caac.20107.
[3]
谢幸，孔北华，段涛. 妇产科学 [M]. 9版．北京：人民卫生出版社，2018：298-302.
[4]
Han X, Wen H, Ju X, et al. Predictive factors of para-aortic lymph nodes metastasis in cervical cancer patients: a retrospective analysis based on 723 para-aortic lymphadenectomy cases [J]. Oncotarget, 2017, 8(31): 51840-51847. DOI: 10.18632/oncotarget.16025.
[5]
Nanthamongkolkul K, Hanprasertpong J. Predictive factors of pelvic lymph node metastasis in early-stage cervical cancer [J]. Oncol Res Treat, 2018, 41(4): 194-198. DOI: 10.1159/000485840.
[6]
Koh WJ, Abu-Rustum NR, Bean S, et al. Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2019, 17(1): 64-84. DOI: 10.6004/jnccn.2019.0001.
[7]
Tanaka T, Sasaki S, Tsuchihashi H, et al. Which is better for predicting pelvic lymph node metastases in patients with cervical cancer: fluorodeoxyglucose-positron emission tomography/computed tomography or a sentinel nodebiopsy? A retrospective observational study [J]. Medicine (Baltimore), 2018, 97(16): e0410. DOI: info:doi/10.1097/MD.0000000000010410.
[8]
SKoh WJ, Greer BE, Abu-Rustum NR, et al. Cervical cancer, version 2.2015 [J]. J Natl Compr Canc Netw, 2015, 13(4): 395-404. DOI: 10.6004/jnccn.2015.0055
[9]
Kim SI, Lim MC, Lee JS, et al. Impact of lower limb lymphedema on quality of life in gynecologic cancer survivors after pelvic lymph node dissection [J]. Eur J Obstet Gynecol Reprod Biol, 2015, 192：31-36. DOI: 10.1016/j.ejogrb.2015.06.011.
[10]
Kim JH, Kim DY, Suh DS, et al. The efficacy of sentinel lymph node mapping with indocyanine green in cervical cancer [J]. World J Surg Oncol, 2018, 16(1): 52. DOI: 10.1186/s12957-018-1341-6.
[11]
Tanaka T, Terai Y, Ono YJ, et al. Genitofemoral neuropathy after pelvic lymphadenectomy in patients with uterine corpus cancer [J]. Int J Gynecol Cancer, 2015, 25(3): 533-536. DOI: 10.1097/IGC.0000000000000335.
[12]
Singh R, Mishra MK, Aggarwal H. Inflammation, immunity, and cancer [J]. Mediators Inflamm, 2017, 2017: 6027305. DOI: 10.1155/2017/6027305.
[13]
Nie D, Gong H, Mao X, et al. Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: a retrospective study [J]. Gynecol Oncol, 2019, 152(2): 259-264. DOI: 10.1016/j.ygyno.2018.11.034.
[14]
Lin JX, Lin JP, Xie JW, et al. Prognostic importance of the preoperative modified systemic inflammation score for patients with gastric cancer [J]. Gastric Cancer, 2019, 22(2): 403-412. DOI: 10.1007/s10120-018-0854-6.
[15]
Chen L, Zhang F, Sheng XG, et al. Decreased pretreatment lymphocyte/monocyte ratio is associated with poor prognosis in stage Ⅰb1-Ⅱa cervical cancer patients who undergo radical surgery [J]. Onco Targets Ther, 2015, 8: 1355-1362. DOI: 10.2147/OTT.S82174.
[16]
Hu RJ, Ma JY, Hu G. Lymphocyte-to-monocyte ratio in pancreatic cancer: prognostic significance and Meta-analysis [J]. Clin Chim Acta, 2018, 481: 142-146. DOI: 10.1016/j.cca.2018.03.008.
[17]
D′Andrea D, Moschini M, Gust KM, et al. Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy [J]. J Surg Oncol, 2017, 115(4): 455-461. DOI: 10.1002/jso.24521.
[18]
Matsuo K, Machida H, Mandelbaum RS, et al. Validation of the 2018 FIGO cervical cancer staging system [J]. Gynecol Oncol, 2019, 152(1): 87-93. DOI: 10.1016/j.ygyno.2018.10.026.
[19]
D′Andrea D, Moschini M, Gust KM, et al. Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy [J]. J Surg Oncol, 2017, 115(4): 455-461. DOI: 10.1002/jso.24521.
[20]
Lu C, Zhou L, Ouyang J, et al. Prognostic value of lymphocyte-to-monocyte ratio in ovarian cancer: a Meta-analysis [J]. Medicine (Baltimore), 2019, 98(24): e15876. DOI: 10.1097/MD.0000000000015876.
[21]
Sun Y, Zhang L. The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a Meta-analysis [J]. Cancer Manag Res, 2018, 10: 6167-6179. DOI: 10.2147/CMAR.S171035.
[22]
Li M, Deng Q, Zhang L, et al. The pretreatment lymphocyte to monocyte ratio predicts clinical outcome for patients with urological cancers: a Meta-analysis [J]. Pathol Res Pract, 2019, 215(1): 5-11. DOI: 10.1016/j.prp.2018.10.026.
[23]
Song L, Zhu J, Li Z, et al. The prognostic value of the lymphocyte-to-monocyte ratio for high-risk papillary thyroid carcinoma [J]. Cancer Manag Res, 2019, 11: 8451-8462. DOI: 10.2147/CMAR.S219163.
[24]
Zhou Z, Li W, Zhang F, et al. The value of squamous cell carcinoma antigen (SCCa) to determine the lymph nodal metastasis in cervical cancer: a Meta-analysis and literature review [J]. PLoS One, 2017, 12(12): e0186165. DOI: 10.1371/journal.pone.0186165.
[25]
Yang H, Hu H, Gou Y, et al. Combined detection of Twist1, Snail1 and squamous cell carcinoma antigen for the prognostic evaluation of invasion and metastasis in cervical squamous cell carcinoma [J]. Int J Clin Oncol, 2018, 23(2): 321-328. DOI: 10.1007/s10147-017-1210-2.
[26]
Tang Y, Li J, Hu HQ, et al. Analysis of correlation between preoperative lymphocyte-to-monocyte ratio and FIGO stage of ovarian cancer [J]. Chin J Prac Gynecol Obstet, 2018, 34(1): 106-109. DOI：10.19538/j.fk2018010123.
[1] 石皆春, 范子玉, 邢燕. 不同筛查方法预警宫颈原位腺癌的效能[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 575-581.
[2] 高伟聪, 李丽, 张中华, 朱向辉, 刘素巧. 宫颈癌患者糖调节受损对改良根治术后2年内复发的影响作用[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(02): 231-237.
[3] 何欣林, 阎昊铮, 赵亦非, 江彩霞, 李征宇. 新辅助化疗联合间歇性肿瘤细胞减灭术对上皮性卵巢癌患者预后及血清学与影像学指标对患者预后的预测价值[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(01): 47-57.
[4] 贺媛媛, 李佳, 杨红. 宫颈中肾腺癌1例并文献复习[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(01): 97-104.
[5] 刘哲魁, 马文星, 聂灵芝, 吴云桦, 单良, 王泽正. HALP评分联合术前检查预测老年胃癌淋巴结转移的价值[J/OL]. 中华普通外科学文献(电子版), 2024, 18(03): 209-215.
[6] 张锐, 赵舸. T1和T2期胆囊癌外科治疗研究进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(03): 225-228.
[7] 贺斌, 马晋峰. 胃癌脾门淋巴结转移危险因素[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 694-699.
[8] 达热拜·热达提, 刘林, 赵为民, 孟涛, 雷程, 金博, 毕建军, 李新宇, 王海江. 中低位直肠癌新辅助放化疗后侧方淋巴结清扫术的临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 415-418.
[9] 吴波, 郑永明, 杜世强. SPECT/CT及血清sTg水平预测甲状腺癌术后131I治疗患者淋巴结转移风险的价值分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(02): 212-216.
[10] 林逸, 钟文龙, 李锴文, 何旺, 林天歆. 广东省医学会泌尿外科疑难病例多学科会诊（第15期）——转移性膀胱癌的综合治疗[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 648-652.
[11] 张艺萱, 罗金丹, 葛小丽, 钟红琴. 先天性心脏病伴PH血清H-FABP、NT-proBNP与肺动脉内径、血流速度及PASP的关系[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(02): 252-255.
[12] 赵月, 田坤, 张宗明, 郭震天, 刘立民, 张翀, 刘卓. 降钙素原对老年急性重度胆囊炎发生的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 801-806.
[13] 马燕芳, 高修银, 李平静, 李雷. 甘油三酯葡萄糖乘积指数与消化性溃疡出血的相关性分析[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(02): 128-131.
[14] 黎璞, 生秀杰. 妊娠合并子宫颈癌的管理[J/OL]. 中华产科急救电子杂志, 2024, 13(04): 202-208.
[15] 彭小蓉, 莫伟, 李琴, 吴雅琴, 李兰. 妊娠期妇女静脉血栓栓塞症预防的知信行现状及其影响因素分析[J/OL]. 中华介入放射学电子杂志, 2024, 12(03): 274-280.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号